Shares of GlaxoSmithKline PLC (NYSE:GSK) reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $35.84 and last traded at $36.14, with a volume of 3561755 shares changing hands. The stock had previously closed at $36.15.

A number of analysts have recently issued reports on the stock. Investec lowered shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Monday. BidaskClub downgraded shares of GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a report on Monday, July 24th. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Monday, July 24th. Citigroup Inc. reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Thursday, July 27th. Finally, TheStreet cut shares of GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research note on Wednesday, July 26th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have given a buy rating to the company’s stock. GlaxoSmithKline PLC currently has an average rating of “Hold” and a consensus target price of $44.33.

The company has a debt-to-equity ratio of 2.96, a quick ratio of 0.44 and a current ratio of 0.64. The company has a market cap of $86,930.00, a P/E ratio of 12.82, a price-to-earnings-growth ratio of 2.00 and a beta of 1.00.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 11th. Shareholders of record on Friday, November 10th will be paid a dividend of $0.5037 per share. This represents a $2.01 annualized dividend and a yield of 5.58%. The ex-dividend date is Thursday, November 9th. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.49. GlaxoSmithKline PLC’s payout ratio is 158.40%.

Large investors have recently added to or reduced their stakes in the business. Proficio Capital Partners LLC grew its stake in GlaxoSmithKline PLC by 233.0% during the 1st quarter. Proficio Capital Partners LLC now owns 2,844 shares of the pharmaceutical company’s stock valued at $122,000 after acquiring an additional 1,990 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its stake in shares of GlaxoSmithKline PLC by 1.9% in the 2nd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company’s stock valued at $137,000 after buying an additional 64 shares in the last quarter. FTB Advisors Inc. grew its stake in shares of GlaxoSmithKline PLC by 16.9% in the 2nd quarter. FTB Advisors Inc. now owns 3,735 shares of the pharmaceutical company’s stock valued at $146,000 after buying an additional 539 shares in the last quarter. Quadrant Capital Group LLC grew its stake in shares of GlaxoSmithKline PLC by 3.5% in the 2nd quarter. Quadrant Capital Group LLC now owns 4,345 shares of the pharmaceutical company’s stock valued at $162,000 after buying an additional 148 shares in the last quarter. Finally, Parallel Advisors LLC grew its stake in shares of GlaxoSmithKline PLC by 93.4% in the 2nd quarter. Parallel Advisors LLC now owns 4,048 shares of the pharmaceutical company’s stock valued at $164,000 after buying an additional 1,955 shares in the last quarter. 9.29% of the stock is currently owned by institutional investors.

WARNING: This article was first posted by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.watchlistnews.com/glaxosmithkline-plc-gsk-sets-new-52-week-low-at-35-84/1685951.html.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.